Eisai Reports Results of Lenvima (lenvatinib) + Everolimus in P-II 218 Study for Advanced Renal Cell Carcinoma
Shots:
- The P-II 218 study involves assessing Lenvima (14mg- qd) + everolimus (5mg- qd) vs Lenvima (18mg- qd) + everolimus (5mg qd) in patients with clear-cell RCC- following treatment with an anti-angiogenic therapy- with prior anti-PD-1/PD-L1 therapy permitted
- In the primary analysis- @24wks. ORR (32.1% vs 34.8%) i.e. lower dose did not meet the threshold for non-inferiority; Grade 2/ any ≥ Grade 3 TEAEs (82.8% vs 79.6%); discontinuation (32.4% vs 26.8%); dose interruption (74.6% vs 83.3%); dose reductions (67.6% vs 69.6%)
- Overall ORR (34.6% vs 40.6%); mPFS (11.1 vs 14.7mos.); m-OS (27.0 vs NE). Results were presented at IKCS 2020
Ref: PRNewswire | Image: Welwyn Hatfield Times
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com